scholarly journals Are the clinical manifestations of CT scan and location associated with World Health Organization histopathological grades of meningioma?: A retrospective study

2021 ◽  
pp. 102365
Author(s):  
Razieh behzadmehr ◽  
Rezvaneh behzadmehr
2020 ◽  
Vol 7 (1A) ◽  
pp. 271-287
Author(s):  
Amalia Dwi Ariska ◽  
Trining Poernomo

Latar belakang: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) merupakan virus penyebab COVID-19 (Corona Virus Disesease-2019) yang pertama kali muncul di Kota Wuhan, Provinsi Hubei, Cina pada akhir Desember 2019. Sejak kemunculannya, SARS COV-2 menunjukkan penambahan jumlah pasien dan kematian yang pesat hingga lintas negara sehingga pada tanggal 11 Maret 2020, WHO (World Health Organization) mengumumkan bahwa COVID-19 dinyatakan sebagai global pandemi. Manifestasi COVID-19 dilaporkan sangat bervariasi, mulai dari gangguan sistem pernafasan, pencernaan, bahkan okular. Namun karena kelangkaan kasus dan situasi pandemi sehingga literatur mengenai manifestasinya pada mata sangat terbatas. Tujuan: Artikel ini akan menelaah manifestasi klinis SARS-COV-2 pada mata, hubungannya dengan manifestasi sistemik, peran pemeriksaan PCR swab konjungtiva, dan terapi yang diberikan melalui review kualitatif sesuai dengan rekomendasi PRISMA. Diskusi dan pembahasan masalah: Terdapat 12 dokumen yang ditelaah dalam review ini. Selain gejala pernafasan, COVID-19 juga dilaporkan dapat menyebabkan konjungtivitis dengan ciri umum seperti mata merah, kemosis konjungtiva, mata berair maupun manifestasi okular lain yang lebih jarang. Manifestasi okular dapat sebagai gejala tunggal, prodromal, maupun bersamaan dengan manifestasi sistemik, dan bisa menyebabkan gejala sisa berupa floaters. Terapinya pun bervariasi berdasarkan gejala. Pada kasus COVID-19 dengan konjungtivitis hasil pemeriksaan PCR swab konjungtiva bisa positif maupun negatif. Kesimpulan: Dapat disimpulkan bahwa manifestasi okular pada pasien COVID-19 mungkin saja terjadi, dan hubungannya dengan manifestasi sistemik sangat bervariasi. Untuk terapi perlu dilakukan penelitian lebih lanjut, dan banyak faktor yang menyebabkan hasil PCR swab konjungtiva tidak sesuai dengan klinis pasien. Sehingga diharapkan agar setiap tenaga kesehatan untuk selalu waspada dan mengambil tindakan pencegahan yang memadai terlepas dari ada atau tidaknya manifestasi okular. Kata kunci : SARS CoV-2; COVID-19; manifestasi okular; konjungtivitis; PCR; swab konungtiva.     Background: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is a virus that causes COVID-19 (Corona Virus Disesease-2019) which first appeared in Wuhan City, Hubei Province, China at the end of December 2019. Since its emergence, SARS COV-2 showed a rapid enhancement in the number of patients and death cases across countries, because of that, on March 11th, 2020, WHO (World Health Organization) announced that COVID-19 was declared as a global pandemic. The manifestations of COVID-19 were reported to be very varied, ranging from disorders of the respiratory, digestive, and even ocular system. However, due to the scarcity of cases and pandemic situations, the literature of its manifestations in the eyes is very limited. Objective: This article will review the clinical manifestations of SARS-COV-2 in the eye, their relationship to systemic manifestations, the PCR examination of conjunctival swab’s roles, and therapy provided through qualitative reviews according to PRISMA recommendations. Discussion: There were 12 documents reviewed in this study. In addition to respiratory symptoms, COVID-19 was also reported to cause conjunctivitis with common features such as red eye, conjunctival chemosis, watery discharge or other ocular manifestations that were less common. Ocular manifestations could be a single symptom, prodromal, or concurrent with systemic manifestations, and could cause sequelae in the form of floaters. Its treatment also varied based on symptoms. In the case of COVID-19 with conjunctivitis the results of conjunctival swab PCR examination could be positive or negative. Conclusion: It can be concluded that ocular manifestations in COVID-19 patients may occur, and their relationship with systemic manifestations is varies. For therapy, further research is needed, and many factors cause the conjunctival swab PCR results to be incompatible with the patient's clinical course. We hope that every health worker must be aware and take precautions regardless of the presence or absence of ocular manifestations. Keywords: SARS CoV-2; COVID-19; ocular manifestations; conjunctivitis; PCR; conjunctival swab.


2021 ◽  
Vol 75 ◽  
pp. 58-63
Author(s):  
Martyna Biała ◽  
Edyta Lelonek ◽  
Brygida Knysz

In December 2019 the first cases of atypical pneumonia caused by a novel coronavirus SARS-CoV-2 were reported in Wuhan, China. This new infection was called coronavirus disease 2019 (COVID-19). SARS-CoV-2 is primarily transmitted human-to-human via direct contact and via the air-respiratory droplets and/or aerosols. The clinical manifestations of COVID-19 could range from asymptomatic or mild non-specific symptoms to severe pneumonia with multiple organ failure and death. The virus spread rapidly to almost all the countries in the world within a few months, and on the 11th of March 2020, the World Health Organization (WHO) announced the COVID-19 pandemic. Since then, a dynamic increase in the number of COVID-19 infections and deaths has been recorded worldwide. The COVID-19 pandemic is accelerating and causing annex tensive impact on the functioning of health care and is also leading to an economic crisis in the world. Today, it is difficult to ultimately assess the long-term effects of the pandemic, although it is known that they will be experienced for decades. Therefore, the most important goal is to stop the pandemic and develop an effective vaccine against SARS-CoV-2. Using the ClinicalTrials.gov and World Health Organization databases, we shed light on the current worldwide clinical and pre-clinical trials in search for a COVID-19 vaccine.


2016 ◽  
Vol 93 ◽  
pp. 478 ◽  
Author(s):  
Wellingson da Silva Paiva ◽  
Fernando Roberto Gondim Cabral de Vasconcelos ◽  
Manoel Jacobsen Teixeira

2019 ◽  
Author(s):  
Balgees A. Ajlan ◽  
Maram M. Alafif ◽  
Maha M. Alawi ◽  
Naeema A. Akbar ◽  
Eman K. Aldigs ◽  
...  

AbstractThe objective of this observational study was to assess the validity of the new dengue classification proposed by the World Health Organization (WHO) in 2009 and to develop pragmatic guidelines for case triage and management. This retrospective study involved 357 laboratory-confirmed cases of dengue infection diagnosed at King Abdulaziz University Hospital, Jeddah, Saudi Arabia over a 4-year period from 2014 to 2017. The sensitivity of the new classification for identifying severe cases was limited (65.0%) but higher than the old one (30 0%). It had a higher sensitivity for identifying patients who needed advanced healthcare compared to the old one (72.0% versus 32.0%, respectively). We propose adding decompensation of chronic diseases and thrombocytopenia-related bleeding to the category of severe dengue in the new classification. This modification improves sensitivity from 72.0% to 97.5% for identifying patients who need advanced healthcare without altering specificity (96.7%). It also improves sensitivity in predicting severe outcomes from 32% to 88.0%. In conclusion, the new classification had a low sensitivity for identifying patients needing advanced care and for predicting morbidity and mortality. We propose to include decompensation of chronic diseases and thrombocytopenia-related bleeding to the category of severe dengue in the new classification to improve the sensitivity of predicting cases requiring advanced care.Author summaryDengue fever, the most prevalent arthropod-borne viral disease in human, has been conventionally classified into four main categories: non-classical, classical, dengue hemorrhagic fever, and dengue shock syndrome. Several studies reported lack of correlation between the categories of the conventional classification and the disease severity. As a consequence, the World Health organization proposed in 2008 a new classification that divides dengue into two categories: non-severe and severe dengue; the non-severe dengue is further divided into two categories: dengue with warning signs and dengue without warning signs. In this retrospective study we reviewed 357 cases of dengue diagnosed in our institution over a 4-year period to assess the validity of the new dengue classification in order to develop pragmatic guidelines for case triage and management in the Emergency Departments. We found that the sensitivity of the new classification for identifying severe cases was limited even though it had a higher sensitivity for identifying patients who needed advanced healthcare compared to the old one. We propose adding decompensation of chronic diseases and low platelets-related bleeding to the category of severe dengue in the new classification. This modification dramatically improves the sensitivity for identifying patients who need advanced healthcare and the sensitivity to predict severe outcomes.


Sign in / Sign up

Export Citation Format

Share Document